Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia. (Q38851847)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27255405%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

review article

1 reference

title

Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27255405%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27255405%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27255405%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Eduard Parellada

1 reference

7 September 2017

Miquel Bioque

series ordinal

1 reference

7 September 2017

publication date

1 August 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27255405%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

number of pages

1 reference

inferred from page(s)

published in

CNS Drugs

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27255405%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27255405%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27255405%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

page(s)

689-701

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27255405%20AND%20SRC:MED&resulttype=core&format=json

Assessment of adherence problems in patients with serious and persistent mental illness: recommendations from the Expert Consensus Guidelines

3 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Patients' and clinicians' attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Examining adherence to medication and substance use as possible confounds of duration of untreated psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Symptoms, cognition, treatment adherence and functional outcome in first-episode psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Medication adherence of individuals with a first episode of psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Treatment adherence in schizophrenia: a patient-level meta-analysis of combined CATIE and EUFEST studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Historical perspective on antipsychotic long-acting injections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Clinical guideline recommendations for antipsychotic long-acting injections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Long-acting injectable antipsychotics in first-episode schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

The case for long-acting antipsychotic agents in the post-CATIE era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Comparison of drug adherence rates among patients with seven different medical conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Depot antipsychotic drugs. Place in therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Clinical experience and management considerations with long-acting risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Long-Acting Risperidone and Oral Antipsychotics in Unstable Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Olanzapine long-acting injection: a review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Tolerability of initiation doses of once-monthly paliperidone palmitate in patients with recently diagnosed schizophrenia in an acute treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Incidence of tardive dyskinesia: a comparison of long-acting injectable and oral paliperidone clinical trial databases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

A qualitative study of the attitudes of patients in an early intervention service towards antipsychotic long-acting injections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Systematic review of patient and nurse attitudes to depot antipsychotic medication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

On the path to recovery: patients' experiences of treatment with long-acting injections of antipsychotic medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Psychiatrists' use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

The challenge of offering long-acting antipsychotic therapies: a preliminary discourse analysis of psychiatrist recommendations for injectable therapy to patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Psychiatrists' attitude to antipsychotic depot treatment in patients with first-episode schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Attitudinal barriers to prescribing LAI antipsychotics in the outpatient setting: communicating with patients, families, and caregivers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Long-acting formulations of atypical antipsychotics: time to reconsider when to introduce depot antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Should long-acting (depot) antipsychotics be used in early schizophrenia? A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Long-acting injectable antipsychotics in early psychosis: a literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Psychiatrists' awareness of partial and nonadherence to antipsychotic medication in schizophrenia: results from an Asia-Pacific survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Relapse in schizophrenia: costs, clinical outcomes and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Barriers to, and strategies for, starting a long acting injection clinic in a community mental health center

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Resource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Estimated economic benefits from low-frequency administration of atypical antipsychotics in treatment of schizophrenia: a decision model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Healthcare utilization and costs of Veterans Health Administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0350-7

Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability - a review

21 January 2018

1 reference

12 December 2020

Long-acting injectable antipsychotics for first-episode schizophrenia: the pros and cons

1 reference

12 December 2020

The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update.

1 reference

12 December 2020

Efficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia: a multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole

1 reference

12 December 2020

Patient-Centered Outcomes with Aripiprazole Once-Monthly for Maintenance Treatment in Patients with Schizophrenia: Results From Two Multicenter, Randomized, Double-Blind Studies

1 reference

12 December 2020

Practice guideline for the treatment of patients with schizophrenia, second edition.

1 reference

12 December 2020

Hospitalisation Utilisation and Costs in Schizophrenia Patients in Finland before and after Initiation of Risperidone Long-Acting Injection

1 reference

12 December 2020

A survey of the attitudes of chronic psychiatric patients living in the community toward their medication

1 reference

12 December 2020

Long-acting injectable antipsychotics: an underutilized treatment option

1 reference

12 December 2020

A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: part II-physician perspectives

1 reference

12 December 2020

An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia.

1 reference

12 December 2020

Rethinking the role of long-acting atypical antipsychotics in the community setting

1 reference

12 December 2020

Clinical practice guidelines. Treatment of schizophrenia.

1 reference

12 December 2020

Long-acting injectable antipsychotics: recommendations for clinicians

1 reference

12 December 2020

A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia

1 reference

12 December 2020

Compliance with antipsychotic drug treatment: influence of side effects.

1 reference

12 December 2020

Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study

1 reference

12 December 2020

Long-acting injectable antipsychotics: shall the last be first?

1 reference

12 December 2020

Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial

1 reference

12 December 2020

Expanding Therapy With Long-Acting Antipsychotic Medication in Patients With Schizophrenia

1 reference

12 December 2020

Why are Canadians complacent about long-acting injectable antipsychotic therapies? Come on, Canada, you can do better!

1 reference

12 December 2020

Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics

1 reference

12 December 2020

A prospective flexible-dose study of paliperidone palmitate in nonacute but symptomatic patients with schizophrenia previously unsuccessfully treated with oral antipsychotic agents

1 reference

12 December 2020

Barriers to utilizing long-acting injectable antipsychotic medications

1 reference

12 December 2020

A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: Part I-patient perspectives

1 reference

12 December 2020

The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness.

1 reference

12 December 2020

[Guidelines on long-acting injectable atypical antipsychotics for first-episode schizophrenia]

1 reference

12 December 2020

Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature

1 reference

12 December 2020

10.1007/S40263-016-0350-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27255405%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27255405%20AND%20SRC:MED&resulttype=core&format=json